A joint initiative between Lung Cancer Canada, The Lung Ambition Alliance and AstraZeneca Canada, the Lung Ambition Awards program is a Canadian-based lung cancer research awards program designed to help address key gaps in lung cancer care and improve the patient pathway.
Awards will be granted to research being done to improve patient care in any of the following three key areas:
Including research into methodologies like screening, incidental pulmonary nodules and blood-based testing, particularly for those individuals not meeting current screening criteria.
Including ways in which institutions or health care systems can improve care along the patient pathway.
Including identification of systemic barriers and ways to overcome them .
All Canadian clinicians and researchers who work in the lung cancer space (across the multi-disciplinary spectrum) are encouraged to apply for a Lung Ambition Award.
As the program secretariat, Lung Cancer Canada manages and administers the granting of the awards. AstraZeneca Canada has committed $100,000 per year for three years, starting in 2023. The Lung Ambition Awards will award 2 -3 research grants per year, with a maximum award of $50,000 each.
Submissions will be accepted from November 4th, 2024 until February 7th, 2025.
Winners will be announced in April 2025.
Complete information about the Lung Ambition Awards and application guidelines can be found at lccresearch.ca
